NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018
May 07 2018 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing its
prescription Avenova® lid and lash hygiene product for the domestic
eye care market, announces that it will report first quarter 2018
financial results after market close on Thursday, May 10.
Management will hold an investment community conference call that
day to discuss financial results and provide a Company update.
DATE:
Thursday, May 10 TIME: 4:30 p.m. ET / 1:30 p.m. PT DIAL IN:
800-608-8202 from within the U.S. 702-495-1913 from outside the
U.S. Enter conference identification number 9649919
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 11:59
p.m. Eastern time May 20, 2018, by dialing 855-859-2056 from within
the U.S. or 404-537-3406 from outside the U.S. and entering the
conference identification number 9649919. The call will also be
archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for the wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Socialize and Stay informed on NovaBay’s progress:Like
us on FacebookFollow us on TwitterConnect
with NovaBay on LinkedInJoin us
on Google+Visit NovaBay’s Website
NovaBay ContactsFor NovaBay Avenova purchasing
information:Please Call us toll free: 1-800-890-0329 or
email sales@avenova.com.www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180507005418/en/
From the CompanyJack McGovernChief Financial
Officer510-899-8800jmcgovern@novabay.comorInvestor
ContactLHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024